- POSITIVE
Annual Revenue Accent Microcell Mar-2026 Annual Revenue is Rs 356 Cr which is growth of 31.3% YoY.
- POSITIVE
Annual Net Profit Accent Microcell Mar-2026 Annual Net Profit is Rs 44 Cr which is growth of 32.7% YoY.
NSE: ACCENTMIC
Accent Microcell Live Share Price Today, Share Analysis and Chart
aboutAccent Microcell Ltd. is an India-based manufacturer specializing in cellulose-based excipients, primarily Microcrystalline Cellulose (MCC). The company serves diverse industries including pharmaceuticals, nutraceuticals, food and beverages, and ... Read More
639.005.00(0.79%)
15,000
NSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Accent Microcell Stock Price Analysis
Day Price Range0.8% 1 Day return | 639 (LTP) 630649 LowHigh |
|---|---|
Week Price Range7.8% 1 Week return | 639 (LTP) 580.6700 LowHigh |
Month Price Range-5.3% 1 Month return | 639 (LTP) 560700 LowHigh |
52 Week Price Range132.1% 1 Year return | 639 (LTP) 273731.7 LowHigh |
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Accent Microcell annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
19.8% | 21.4% | 355.8 | 271 | 249.1 | 207 | 167.5 | 134.8 | ||
Operating Exp. Ann. | 16.5% | 19.1% | 292.3 | 222.7 | 206 | 184.8 | 152.7 | 121.9 | |
Operating Profit Ann. | 43% | 39.6% | 56.7 | 41.9 | 39.5 | 19.4 | 13 | 10.7 | |
OPM Ann. % | 19.4% | 15% | 15.93% | 15.47% | 15.84% | 9.36% | 7.74% | 7.93% | |
15.8% | 18.2% | 297.5 | 227.2 | 211.6 | 191.5 | 160 | 128.8 | ||
EBITDA Ann. | 42% | 37.5% | 63.5 | 48.3 | 43.1 | 22.2 | 14.8 | 12.9 | |
EBITDA Ann. margin % | 18.5% | 13.2% | 17.84% | 17.83% | 17.30% | 10.71% | 8.83% | 9.60% | |
Interest Ann. | -41.5% | -31.8% | 0.5 | 0.4 | 1.2 | 2.5 | 3.1 | 3.4 | |
Depr. | 4.7% | 5.5% | 4.7 | 4.2 | 4.4 | 4.1 | 4.2 | 3.6 | |
PBT Ann. | 55.5% | 57.6% | 58.3 | 43.8 | 36.5 | 15.5 | 7.6 | 6 | |
Tax Ann. | 79.3% | 64.4% | 14.4 | 10.7 | 6.4 | 2.5 | 1.7 | 1.2 | |
50% | 55.7% | 43.9 | 33.1 | 30.2 | 13 | 5.9 | 4.8 | ||
Net Profit Ann. | 50% | 55.7% | 43.9 | 33.1 | 30.2 | 13 | 5.9 | 4.8 | |
NPM Ann. % | 25.4% | 28.2% | 12.56% | 12.49% | 12.28% | 6.37% | 3.55% | 3.62% | |
EPS Adj. latest Ann. | 50.2% | 55.7% | 18.3 | 13.8 | 12.6 | 5.4 | 2.5 | 2 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
31.3%
2Y CAGR
19.5%
3Y CAGR
19.8%
5Y CAGR
21.4%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
32.6%
2Y CAGR
20.6%
3Y CAGR
50%
5Y CAGR
55.7%
Net Profit Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
31.3%
2Y CAGR
19.1%
3Y CAGR
16.5%
5Y CAGR
19.1%
Operating Expenses Annual Cr growth is higher than historical averages.
Accent Microcell Technical Analysis
Accent Microcell EMA & SMA
Neutral0
4 bullish, 4 bearish
Bullish4
Bearish4
| 5 Day | 635.4 |
|---|---|
| 10 Day | 640.0 |
| 12 Day | 642.0 |
| 20 Day | 647.1 |
| 26 Day | 647.4 |
|---|---|
| 50 Day | 632.0 |
| 100 Day | 583.4 |
| 200 Day | 506.6 |
Accent Microcell Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202653.3%
Week62.8%
Month66.2%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Accent Microcell Resistance and Support
639.35
Pivot
| First Resistance | 648.7 |
|---|---|
| Second Resistance | 658.3 |
| Third Resistance | 667.6 |
| First Support | 629.7 |
|---|---|
| Second Support | 620.4 |
| Third Support | 610.8 |
| Day RSI | 48 |
|---|---|
| Day MACD | -5.3 |
| Day MFI | 63 |
| Day MACD Signal Line | -1 |
Accent Microcell Beta
| 1 Month | 1.4 |
|---|---|
| 1 Year | 0.7 |
| 3 Month | 0.7 |
|---|---|
| 3 Year | - |
Accent Microcell Price Change Analysis
↓-5.3%
Over 1 Month
LowHigh
560700
↑25.8%
Over 3 Months
LowHigh
492.1731.7
↑50.2%
Over 6 Months
LowHigh
411731.7
↑132.1%
Over 1 Year
LowHigh
273731.7
Accent Microcell Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| GHANSHYAM ARJANBHAI PATEL | Bulk | Sell | 20 Jul 2026 | 521.01 | 390,000 | NSE |
| GHANSHYAM ARJANBHAI PATEL | Bulk | Sell | 09 Jun 2026 | 476.95 | 586,000 | NSE |
| KAMLESH B AMIN HUF | Bulk | Purchase | 09 Jun 2026 | 475 | 125,000 | NSE |
| HIMANSHU B. AMIN (HUF) | Bulk | Purchase | 09 Jun 2026 | 479.66 | 125,000 | NSE |
| MANOJ AGARWAL HUF | Bulk | Purchase | 23 Dec 2024 | 277.20 | 150,000 | NSE |
| MERU INVESTMENT FUND PCC- CELL 1 | Bulk | Sell | 16 Jan 2024 | 303.01 | 240,000 | NSE |
| MANOJ AGARWAL | Bulk | Purchase | 15 Dec 2023 | 298.86 | 120,000 | NSE |
Accent Microcell Corporate Actions
Accent Microcell Dividend history and yield
Accent Microcell dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Accent Microcell dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
117 Jul 2026 | 1 | FINAL | 17 Jul 2026 | Equity Share |
216 Sep 2025 | 1 | FINAL | 16 Sep 2025 | Equity Share |
Accent Microcell Board Meetings
Accent Microcell past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
112 May 2026 | Audited Results, Dividend & Others | To consider other business matters. |
214 Oct 2025 | Quarterly Results & Others | To consider other business matters. |
322 Aug 2025 | Dividend & Others | To consider other business matters. |
429 May 2025 | To Consider Fund Raising & Other | To consider other business matters. |
509 May 2025 | Audited Results & Others | To consider other business matters. |
Accent Microcell Rights issue
Accent Microcell rights issue history, along with record, ex-rights dates, and rights ratios.
#Ex-Date | Ratio | Face Value | Premium | Record Date |
|---|---|---|---|---|
104 Jun 2025 | 7.0:50.0 | 10 | 125 | 04 Jun 2025 |
Accent Microcell Documents
Accent Microcell Credit Ratings
Accent Microcell credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 21 Oct 2026 | crisil ratings | Accent Microcell Limited | Accent Microcell Limited:Issuer not cooperating, based on best-available information; Ratings revised to 'Crisil BB-/Stable/Crisil A4+ Issuer not cooperating\u2019 | Link |
| 24 Mar 2026 | care ratings | Accent Microcell Limited | Link | |
| 26 Feb 2026 | crisil ratings | Accent Microcell Limited | Accent Microcell Limited:Issuer not cooperating, based on best-available information; Ratings revised to \u2018Crisil B/Stable/Crisil A4 Issuer not cooperating\u2019 | Link |
| 19 Mar 2025 | care ratings | Accent Microcell Limited | Link | |
| 26 Dec 2024 | crisil ratings | Accent Microcell Limited | Accent Microcell Limited:Issuer not cooperating, based on best-available information; Ratings continues to be \u2018CRISIL B+/Stable/CRISIL A4 Issuer not cooperating' | Link |
Accent Microcell - Company Profile
Accent Microcell Management Structure
Accent Microcell management structure with salaries, total experience, and qualifications.
Accent Microcell Board of Directors
Accent Microcell Board of directors with salaries, total experience, and qualifications.
Website: www.accentmicrocell.com
About the company - Business Profile
Accent Microcell Ltd. is an India-based manufacturer specializing in cellulose-based excipients, primarily Microcrystalline Cellulose (MCC). The company serves diverse industries including pharmaceuticals, nutraceuticals, food and beverages, and cosmetics. Accent Microcell has established a significant presence in both domestic and international markets, exporting to over 45 countries, including the USA, Canada, Germany, and the UK.
Key Points
Key Facts
- Founded Year: 2001 (Incorporated as a private limited company).
- Headquarters: Ahmedabad, Gujarat, India.
- Stock Listing: Listed on the NSE SME platform (Emerge) following its Initial Public Offering in December 2023.
- Primary Products: Microcrystalline Cellulose (MCC), Carboxymethyl Cellulose (CMC), Croscarmellose Sodium (CCS), and other excipients.
Operations and Resources
- Manufacturing Facilities: The company operates two state-of-the-art manufacturing units:
- Unit I: Located in Pirana Road, Ahmedabad.
- Unit II: Located in Dahej SEZ, Bharuch, Gujarat.
- Integration: The Dahej facility is a 100% Export Oriented Unit (EOU), strategically located to serve international clients efficiently.
- Capacity: As of recent filings, the company has an aggregate manufacturing capacity of approximately 8,000 metric tonnes per annum (MTPA).
Market and Significance
- Industries Served: Predominantly pharmaceutical (tablets/capsules formulation), food (stabilizers), and cosmetics (texturizers).
- Strategic Importance: It is one of the leading manufacturers of MCC in India, competing with major players like Sigachi Industries. The company provides more than 20 grades of MCC, tailored for specific moisture levels and particle sizes.
Business Model and Strengths
- Model: Focuses on high-quality production of specialized excipients that act as binders and disintegrants in drug manufacturing.
- Strengths: Extensive product range (MCC grades 101, 102, 112, etc.), a robust global distribution network, and adherence to international quality standards (USP, BP, EP, and JP).
Revenue Breakdown (FY 2023-24)
- Total Revenue from Operations: ₹247.33 crore.
- Net Profit: ₹30.34 crore.
- Geographical Breakdown:
- Exports: Historically contributes approximately 70% - 75% of total revenue.
- Domestic: Contributes the remaining 25% - 30%.
Innovation and Future Outlook
- Strategic Initiatives: Utilizing IPO proceeds for setting up a new plant at Navagam, Kheda, to manufacture Croscarmellose Sodium (CCS) and Sodium Starch Glycolate, further diversifying its excipient portfolio.
- Innovation: Continuous development of "Ready-to-use" co-processed excipients to simplify drug manufacturing processes for pharmaceutical clients.
Employee and Human Resources
- Employee Count: Approximately 200+ employees across manufacturing and corporate functions.
